Speaker Profile
M.D., Ph.D., Chief of Stanford BMT and Cell Therapy Program, Stanford
Biography
Dr. Miklos is the Chief of Stanford BMT and Cell Therapy Program that provides 750 cancer cell therapies annually. Our BMT-CT research fosters the development of both laboratory immunologists, and clinical translational researchers. Our allogeneic hematopoietic cell transplantation (alloHCT) research is optimizing graft content of HSC, conventional T lymphocyte, and regulatory T cell content in order to cures blood cancers via beneficial graft-v-tumor (GVT) immunity while reducing GVHD risk. Our CAR-T research provides the most direct targeting of cancer and is dramatically improving leukemia and Lymphoma with no GVHD risk. Our goal is to combine graft engineered allogeneic HCT with CAR-T benefit. The Miklos lab pioneered protein microarray technologies to discover clinically relevant allogeneic antibodies. Our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. More recently, our team developed human correlative assays to optimize CAR-T therapy including ctDNA MRD, flow cytometry tumor antigen quantification, Immune phenotype CAR-T characterization (CAR-FACS), and single cell RNA characterization of CAR-T cells. Immunotherapy is revolutionizing cancer treatment and Stanford Cancer Cell Therapy Program is developing and evaluating the most promising chimeric antigen T-cell (CAR-T) therapies targeting CD19, CD20, CD22, CD79A, and BCMA.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: The Industrialization of Cell Therapy:From Autologous Pioneers to Allogeneic Frontiers
• Arie S. Belldegrun, Allogene Therapeutics
Next Generation CAR-T Cell Therapies: Expanding Targets and Enhancing Designs
• Chair: Erin Harris Cell & Gene
• David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
PMWC Award Ceremony
• Michel Sadelain, Columbia University
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Stanford
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• Zach Roberts, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Priti Hegde, Kite Pharma
Smart Scaling: Leverating AI & Automation to De-Risk Advanced Therapy Manufacturing
• Chair: Stacie Calad-Thomson
• Samuel Rodriques, FutureHouse
• Manuel Leonetti, Biohub
• Fabian Gerlinghaus, Cellares
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
In Vivo CAR Therapy: Immune Reprogramming Directly in Patients
• Daniel Getts, Myloid Therapeutics
Operationalizing Cell & Gene Therapy Trials in a Large Health System
•Snehit Prabhu, Stanford
Gene Editing & Synthetic Biology for Therapy
• Chair: Trevor Martin, Mammoth Biosciences
• Ken Drazan, ArsenalBio
• Lynn Seely, Lyell
• Kole T. Roybal, Parker Institute
• David Kirn, 4DMT
